Clinical Trial Detail

NCT ID NCT03358719
Title DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

chronic myelomonocytic leukemia

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa

Age Groups: adult senior

No variant requirements are available.